ETF Holdings Breakdown of EWTX

Stock NameEdgewise Therapeutics Inc
TickerEWTX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS28036F1057

News associated with EWTX

Dimensional Fund Advisors LP Grows Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Dimensional Fund Advisors LP grew its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 0.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 729,923 shares of the company’s stock after buying an additional 3,052 shares during […] - 2025-05-08 07:50:47
Envestnet Asset Management Inc. Grows Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Envestnet Asset Management Inc. increased its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 32.0% in the 4th quarter, HoldingsChannel reports. The fund owned 14,678 shares of the company’s stock after purchasing an additional 3,561 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Edgewise Therapeutics were worth $392,000 at the end […] - 2025-05-06 07:24:53
Edgewise Therapeutics (NASDAQ:EWTX) Earns Buy Rating from Analysts at Guggenheim
Guggenheim initiated coverage on shares of Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The firm set a “buy” rating and a $41.00 price target on the stock. Guggenheim’s price target suggests a potential upside of 145.80% from the stock’s current price. Other […] - 2025-05-02 08:02:53
Invesco Ltd. Sells 21,341 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Invesco Ltd. lowered its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 32.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 43,435 shares of the company’s stock after selling 21,341 shares during the quarter. Invesco Ltd.’s holdings in Edgewise Therapeutics were worth $1,160,000 as of its most recent […] - 2025-05-02 07:26:44
Marshall Wace LLP Sells 547,672 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Marshall Wace LLP reduced its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 94.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,893 shares of the company’s stock after selling 547,672 shares during the period. […] - 2025-05-01 08:43:00
Barclays PLC Has $3.57 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Barclays PLC grew its position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 12.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 133,657 shares of the company’s stock after purchasing an additional 14,307 shares during the quarter. Barclays PLC’s holdings in Edgewise Therapeutics were worth $3,568,000 at the end of the […] - 2025-04-29 08:08:56
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $40.38 Average PT from Brokerages
Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month […] - 2025-04-24 05:10:55
Edgewise Therapeutics (NASDAQ:EWTX) Receives “Outperform” Rating from Wedbush
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report)‘s stock had its “outperform” rating reissued by Wedbush in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $43.00 price objective on the stock. Wedbush’s price target points to a potential upside of 217.81% from the company’s previous close. Several other research […] - 2025-04-23 06:00:59
Alliancebernstein L.P. Raises Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Alliancebernstein L.P. increased its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 1.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 77,260 shares of the company’s stock after purchasing an additional 1,300 shares during the period. Alliancebernstein L.P.’s holdings […] - 2025-04-17 07:30:59
Geode Capital Management LLC Increases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Geode Capital Management LLC grew its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 0.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,600,571 shares of the company’s stock after purchasing an additional 1,036 shares during the quarter. Geode […] - 2025-04-15 08:08:57
Orion Portfolio Solutions LLC Decreases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Orion Portfolio Solutions LLC decreased its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 8.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 11,928 shares of the company’s stock after selling 1,083 shares during the period. Orion Portfolio Solutions LLC’s holdings in Edgewise Therapeutics were worth $318,000 at the […] - 2025-04-10 08:38:57
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Director Acquires $10,000,000.23 in Stock
Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) Director Orbimed Advisors Llc acquired 496,771 shares of Edgewise Therapeutics stock in a transaction that occurred on Thursday, April 3rd. The stock was acquired at an average price of $20.13 per share, with a total value of $10,000,000.23. Following the completion of the acquisition, the director now […] - 2025-04-07 09:28:50
Scotiabank Downgrades Edgewise Therapeutics (NASDAQ:EWTX) to Sector Perform
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) was downgraded by research analysts at Scotiabank from a “sector outperform” rating to a “sector perform” rating in a research report issued on Wednesday, Marketbeat.com reports. They currently have a $14.00 target price on the stock, down from their prior target price of $50.00. Scotiabank’s price target would […] - 2025-04-04 06:14:47
Noteworthy Wednesday Option Activity: EWTX, PACK, ORCL
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Edgewise Therapeutics Inc (Symbol: EWTX), where a total of 15,988 contracts have traded so far, representing approximately 1.6 million underlying shares. That amounts to - 2025-04-02 19:27:28
Teacher Retirement System of Texas Has $298,000 Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Teacher Retirement System of Texas raised its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 18.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,143 shares of the company’s stock after purchasing an […] - 2025-04-02 07:42:47
Quantbot Technologies LP Purchases Shares of 3,855 Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
Quantbot Technologies LP purchased a new stake in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 3,855 shares of the company’s stock, valued at approximately $103,000. Other institutional investors have also recently made changes to their positions […] - 2025-04-01 07:54:48
AlphaQuest LLC Reduces Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
AlphaQuest LLC reduced its position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 75.6% in the 4th quarter, Holdings Channel reports. The fund owned 2,203 shares of the company’s stock after selling 6,832 shares during the period. AlphaQuest LLC’s holdings in Edgewise Therapeutics were worth $59,000 at the end of the most recent quarter. […] - 2025-03-21 08:06:56
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives $41.29 Average Price Target from Brokerages
Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average […] - 2025-03-05 06:06:48
New York State Common Retirement Fund Increases Stock Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)
New York State Common Retirement Fund lifted its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) by 6.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,366 shares of the company’s stock after purchasing an additional […] - 2025-03-03 09:08:32

EWTX institutional holdings

The following institutional investment holdings of EWTX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 33,283USD 489,260
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 22,227USD 326,737 1.2%
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 45,366USD 666,880
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 45,366USD 666,880 1.2%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 493USD 7,247
Total =146,735 USD 2,157,004
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.